L
Lexeo Therapeutics
Biotech & Life Sciences · New York City, United States · Founded 2018 · IPO 2023
Revolutionizes human health therapeutics by applying the science of gene therapy to treat and cure some of the world’s most devastating genetic and acquired diseases MoreLess
LEXEO Therapeutics, founded in 2018, is a biotechnology company based in New York that specializes in gene therapy. The company focuses on developing treatments for both common and rare diseases, particularly in the areas of cardiac and neurological conditions. Leveraging a strong research foundation from Weill Cornell Department of Genetic Medicine, LEXEO aims to address unmet medical needs through pioneering genetic medicine. The company serves patients who suffer from genetic disorders and collaborates with clinicians and researchers to bring advanced therapies to market. LEXEO operates in the biotech sector, targeting healthcare providers, medical institutions, and patients as its primary clients. The business model is centered around research and development, clinical trials, and eventual commercialization of gene therapies. Revenue is generated through partnerships, grants, and future sales of approved therapies.
Keywords: gene therapy, biotechnology, cardiac diseases, neurological diseases, genetic research, clinical trials, rare diseases, healthcare, biotech sector, medical innovation.
Company overview
Lexeo Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2018
- Headquarters
- New York City, United States
- Employees
- 95
- Open positions
- 14
- Dealroom signal
- 49.7
- Investment activity
- 1 companies · latest Jul 2021
- Capital deployed
- —
- Preferred round
- ACQUISITION
Valuation & funding
Lexeo Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| PRIVATE PLACEMENT NON VCOther financing | Oct 2025 | $10M | — | Balyasny Asset Management | ↗ |
| POST IPO EQUITYOther financing | Oct 2025 | $143M | — | Undisclosed | ↗ |
| PRIVATE PLACEMENT VCOther financing | May 2025 | $80M | — | Woodline Partners · Vestal Point Capital · Janus Henderson Investors · Ally Bridge Group | ↗ |
| POST IPO EQUITYOther financing | Mar 2024 | $95M | — | Adage Capital · Novo Holdings · Braidwell · RA Capital Management | ↗ |
| IPOOther financing | Nov 2023 | $100M | $100M | Undisclosed | ↗ |
| GRANTOther financing | Jan 2022 | Small Business Innovation Research | — | ||
| SERIES BOther financing | Sep 2021 | D1 Capital Partners · Eventide Asset Management | — | ||
| SERIES AOther financing | Jan 2021 | Alexandria Equities · Lundbeckfonden Ventures · Omega Funds · Longitude Capital | — | ||
| GRANTOther financing | Sep 2020 | Alzheimer's Drug Discovery Foundation | — | ||
| SPINOUTOther financing | Jan 2018 | Cornell Tech · Cornell University | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$109M | — |
| 2025 | $0 | — | −$101M | — |
| 2024 | $0 | — | −$96M | — |
| 2023 | $0 | -100% | −$64M | — |
| 2022 | $654K | -60.5% | −$58M | -8874.8% |
| 2021 | $1.7M | +219.6% | −$51M | -3054.3% |
| 2020 | $518K | — | −$4.6M | -884% |
Growth signals
Lexeo Therapeutics website traffic
Latest recorded traffic for Lexeo Therapeutics is 7.6K monthly website visits, down 17.4% over the last three months. Lexeo Therapeutics's team grew 13.1% over the past year.
Hiring
Open positions at Lexeo Therapeutics
Current openings linked to this company in Dealroom.
Comparisons
Lexeo Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Capital deployed
Lexeo Therapeutics investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Talent graph
Lexeo Therapeutics's talent
Source: Dealroom Talent Intelligence.
Investors
24 investors on Lexeo Therapeutics's cap table
Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.
Global footprint
Where Lexeo Therapeutics has talent and traffic
team presence
In the news
Latest news about Lexeo Therapeutics
Recent press, funding announcements, and product moves mentioning Lexeo Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Lexeo Therapeutics
An AI-synthesized read of the highest-engagement posts about Lexeo Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Lexeo Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.